Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Opioid/Benzodiazepine Polydrug Abuse: Aim 3 [Phase 2]
Phase 2 clinical trial update for opioid and benzodiazepine polysubstance abuse (Aim 3); the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder [Phase 2]
A Phase 2 clinical trial assessing the effects of pharmacological stress and repetitive transcranial magnetic stimulation on executive funct…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: rTMS, Stress and Opioid Use Disorder [NA]
Wayne State University reports an ongoing clinical trial evaluating repetitive transcranial magnetic stimulation (rTMS) for opioid use disor…
-
FDA approval · 2025-12-29FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for buprenorphine hydrochloride by Par Health USA, LLC, under ANDA206586.
-
CLINICAL_TRIALS trial_result · 2025-12-29Clinical Trial Update: Determining the Feasibility of Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Opioids [NA]
A completed clinical trial evaluating the feasibility of outpatient parenteral antibiotic therapy for people who inject opioids.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Psilocybin on Brain Mechanisms of Motivation in OUD [Phase 2]
A Phase 2 clinical trial is investigating psilocybin for opioid use disorder, focusing on brain mechanisms of motivation. Recruitment is ong…
-
FDA approval · 2025-12-23FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (VistaPharm, LLC)
The FDA approved a supplemental application for methadone hydrochloride from VistaPharm, LLC.
-
FDA approval · 2025-12-23FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for methadone hydrochloride by VistaPharm, LLC, enabling the marketing of the generic product in the…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Suvorexant for Opioid/Stimulant Co-use [Phase 2]
Phase 2 trial of suvorexant for co-use of opioids and stimulants has completed and posted results.
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Trauma Intervention to Optimize PrEP Among Women Who Inject Drugs [NA]
This clinical trial update describes a study evaluating a trauma-focused intervention to optimize pre-exposure prophylaxis (PrEP) for HIV pr…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: OMAR Opioid Use Disorder [Phase 1]
A Phase 1 clinical trial led by Yale University to evaluate OMAR for opioid use disorder is currently recruiting, with healthy controls incl…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Remote Methadone Ingestion Surveillance Trial (RMIST) [NA]
The Remote Methadone Ingestion Surveillance Trial (RMIST) completed. It studied opioid use disorder and was sponsored by the University of T…
-
FDA approval · 2025-12-22FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for a buprenorphine and naloxone product from Sun Pharmaceutical Industries, Inc., signifying ap…
-
FDA approval · 2025-12-22FDA Approved: METHADOSE — Supplemental Application (SpecGx LLC)
The FDA approved a supplemental application for METHADOSE (methadone hydrochloride) submitted by SpecGx LLC.
-
FDA approval · 2025-12-22FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for methadone hydrochloride in a generic product by Hikma Pharmaceuticals USA Inc.
-
FDA approval · 2025-12-22FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Aurolife Pharma, LLC)
FDA approved a supplemental application for Aurolife Pharma’s methadone hydrochloride product, enabling its marketing as a generic methadone…
-
FDA approval · 2025-12-22FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)
The FDA approved a supplemental application for SUBLOCADE (buprenorphine extended-release) submitted by Indivior Inc.
-
FDA approval · 2025-12-22FDA Approved: SUBOXONE — Supplemental Application (INDIVIOR INC.)
The FDA approved a supplemental application for Suboxone (buprenorphine hydrochloride with naloxone hydrochloride) submitted by Indivior, up…
-
FDA label_change · 2025-12-22FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
The FDA approved a supplemental labeling change for ZUBSOLV (buprenorphine/naloxone) from Orexo US, Inc., updating the product labeling.
-
FDA approval · 2025-12-22FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for buprenorphine hydrochloride and naloxone hydrochloride dihydrate (SpecGx LLC), indicating regula…
-
FDA approval · 2025-12-22FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal's supplemental application for a generic Buprenorphine HCl and Naloxone HCl product for the treatment of opioid use diso…
-
FDA approval · 2025-12-22FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
The FDA approved a supplemental application for Rhodes Pharmaceuticals L.P.'s generic buprenorphine/naloxone product.
-
FDA approval · 2025-12-22FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Accord Healthcare, Inc)
FDA approved a supplemental application for Accord Healthcare's generic buprenorphine hydrochloride and naloxone hydrochloride dihydrate pro…
-
FDA approval · 2025-12-22FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Hikma Pharmaceuticals USA Inc. to market a buprenorphine hydrochloride and naloxone hydrochlorid…
-
FDA approval · 2025-12-22FDA Approved: BRIXADI — Supplemental Application (Braeburn Inc.)
The FDA approved a supplemental application for BRIXADI (buprenorphine) from Braeburn Inc., resulting in updated labeling and/or expanded in…